8-K: Pulse Biosciences Appoints Maria Sainz to Board

Pulse Biosciences strengthens its board with the appointment of Maria Sainz, a seasoned healthcare technology executive, effective January 9, 2026.

Summary

• Pulse Biosciences, Inc. (Nasdaq: PLSE) announced the appointment of Maria Sainz to its Board of Directors, effective January 9, 2026.
• Ms. Sainz brings over three decades of experience in healthcare technology, including 18 years in CEO roles for publicly traded and venture-backed medical device companies.
• She currently serves as President and CEO of Hyperfine, Inc. (NASDAQ: HYPR), a medical technology company with a commercial-stage portable brain MRI system.
• Her previous CEO roles include Aegea Medical (acquired by CooperSurgical), CardioKinetix Inc., and Concentric Medical (acquired by Stryker Corporation).
• Prior to her CEO roles, Ms. Sainz held various leadership positions at Guidant Corporation and Boston Scientific Corporation.
• Ms. Sainz has also been appointed to serve on the company's Audit Committee.
• Her compensation includes an annual retainer of $55,000 for Board service and $13,000 for Audit Committee service, along with an initial stock option grant to purchase 50,000 shares and eligibility for annual grants of 30,000 shares.

Sentiment

Score: 8

Explanation: The appointment of a highly qualified and experienced director with a strong track record in the medical device industry, including CEO roles and M&A experience, is a significant positive for the company's strategic direction and commercialization efforts.

Positives

• Ms. Sainz brings extensive experience (30+ years) in healthcare technology, including 18 years in CEO roles, which is invaluable for guiding growth, commercialization, and scale.
• Her background includes leading successful exits (Aegea Medical acquired by CooperSurgical, Concentric Medical acquired by Stryker Corporation) and achieving significant clinical/regulatory and financing milestones.
• Her strategic and operational expertise in medical device commercialization will be critical as Pulse Biosciences advances its nPulse technology programs.
• Appointment to the Audit Committee suggests strong financial oversight capabilities and enhances corporate governance.

Future Outlook

Maria Sainz's strategic and operational expertise is expected to be invaluable as Pulse Biosciences begins creating and disrupting interventional markets with its patient-first mission. The company anticipates expanding its clinical evidence, accelerating commercialization, and driving short, intermediate, and long-term value creation as its first three programs advance through key clinical, regulatory, and commercial milestones.

Management Comments

• "We are delighted to welcome Maria to our Board of Directors. She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional markets with our patient-first mission." Robert W. Duggan, Co-Chairman of the Board.
• "I am honored to join Pulses Board of Directors at this pivotal stage, as its first three programs advance through key clinical, regulatory, and commercial milestones. Pulse is very well positioned and Nanosecond PFA technology is exceptionally differentiated and has critical applications in large clinical markets. I look forward to working with the leadership team and contributing strategic guidance as the Company expands its clinical evidence, accelerates commercialization, and drives short, intermediate, and long-term value creation." Maria Sainz.

Industry Context

The appointment of a highly experienced executive from the medical technology sector, particularly one with a strong background in commercialization and M&A, signals Pulse Biosciences' intent to accelerate the market penetration of its novel nPulse technology. This aligns with a broader industry trend where innovative bioelectric medicine companies seek seasoned leadership to navigate complex regulatory landscapes and competitive markets. Ms. Sainz's experience with MRI systems (Hyperfine) and interventional therapies (CardioKinetix, Concentric Medical) is directly relevant to Pulse's stated focus on atrial fibrillation and surgical soft tissue ablation.

Comparison to Industry Standards

• The appointment of a director with extensive CEO experience in multiple public and venture-backed medical device companies (e.g., Hyperfine, Aegea Medical, Concentric Medical) is a strong move, often seen in companies aiming for significant growth and market disruption.
• Her board service at companies like Shockwave Medical (NASDAQ: SWAV), Spectranetics Corp (NASDAQ: SPNC), and Avanos Medical (NASDAQ: AVNS) demonstrates a track record of contributing to successful medical technology firms, which is a high standard for board appointments.
• Her experience in negotiating and structuring acquisitions (Aegea Medical, Concentric Medical) is particularly valuable, mirroring the strategic moves of successful medical device companies like Medtronic or Boston Scientific in expanding their portfolios.

Management Changes

Corporate Governance

Related Party Transactions

• No family relationships exist between Ms. Sainz and any director or executive officer of the Company.
• Ms. Sainz has not engaged in any transaction that would be reportable as a related party transaction under Item 404(a) of Regulation S-K.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through enhanced strategic guidance, accelerated commercialization, and improved corporate governance due to Ms. Sainz's expertise.
• Employees: Potential for clearer strategic direction and stronger support for product development and commercialization efforts, fostering a more focused and effective work environment.
• Customers/Providers: Potential for faster market access to Pulse Biosciences' nPulse technology and improved patient outcomes as commercialization efforts accelerate.

Next Steps

• Maria Sainz will serve on the Board until her term expires at the annual meeting of stockholders in 2026.
• The company will continue to advance its first three programs through key clinical, regulatory, and commercial milestones.
• The company aims to expand clinical evidence, accelerate commercialization, and drive value creation with Ms. Sainz's strategic guidance.

Key Dates

Recommendation

The appointment of Maria Sainz, a highly accomplished and experienced leader in the medical device industry, significantly strengthens Pulse Biosciences' strategic capabilities and commercialization prospects. Her proven track record in guiding companies through growth, M&A, and market disruption, coupled with her specific expertise in interventional therapies, positions the company for accelerated success with its novel nPulse technology. This move signals a strong commitment to execution and value creation, making the stock a compelling "strong buy" for investors looking for growth in the bioelectric medicine sector.

Keywords

Pulse Biosciences, Maria Sainz, Board of Directors, Director Appointment, Nanosecond Pulsed Field Ablation, nsPFA, medical device, healthcare technology, corporate governance, Hyperfine, PLSE, Audit Committee